{"id":928,"date":"2020-09-01T15:41:33","date_gmt":"2020-09-01T15:41:33","guid":{"rendered":"https:\/\/news.nnlm.gov\/nphco\/?p=928"},"modified":"2020-09-01T15:44:33","modified_gmt":"2020-09-01T15:44:33","slug":"covid-19-vaccine-candidate-begins-phase-3-clinical-trial","status":"publish","type":"post","link":"https:\/\/news.nnlm.gov\/nphco\/covid-19-vaccine-candidate-begins-phase-3-clinical-trial\/","title":{"rendered":"COVID-19 Vaccine Candidate Begins Phase 3 Clinical Trial"},"content":{"rendered":"<p>Scientists at Rocky Mountain Laboratories in Hamilton, Montana,conducted a preclinical study of the investigational vaccine AZD1222, <a href=\"https:\/\/www.niaid.nih.gov\/news-events\/investigational-chadox1-ncov-19-vaccine-protects-monkeys-against-covid-19-pneumonia\">their findings were <\/a><a href=\"https:\/\/www.nature.com\/articles\/s41586-020-2608-y\" target=\"_blank\" rel=\"noopener noreferrer\" data-extlink=\"\">recently published in\u00a0<em>Nature.<\/em><\/a>\u00a0 AZD122 uses a viral vector to deliver a SARS-CoV-2 spike protein to induce immune response.<\/p>\n<p>See the full news release at <a href=\"https:\/\/www.nih.gov\/news-events\/news-releases\/phase-3-clinical-testing-us-astrazeneca-covid-19-vaccine-candidate-begins\">Phase 3 Clinical Testing in the US of AstraZeneca COVID-19 Vaccine Candidate Begins (August 31, 2020)<\/a><\/p>\n<p>The NIAID\u00a0<a href=\"https:\/\/www.coronaviruspreventionnetwork.org\/clinical-study-locations\/index.html\" target=\"_blank\" rel=\"noopener noreferrer\" data-extlink=\"\">COVID-19 Prevention Network (CoVPN)<\/a> will participate in the Phase 3 clinical trial of AZD1222 in the United States. <a href=\"https:\/\/www.niaid.nih.gov\/news-events\/nih-launches-clinical-trials-network-test-covid-19-vaccines-and-other-prevention-tools\">The CoVPN<\/a> is composed of existing NIAID-supported clinical research networks with infectious disease expertise and is designed for evaluation of vaccine candidates and antibodies for the prevention of COVID-19.<\/p>\n<p>The Phase 3 trial is being implemented as part of\u00a0<a href=\"https:\/\/www.hhs.gov\/about\/news\/2020\/06\/16\/fact-sheet-explaining-operation-warp-speed.html\" target=\"_blank\" rel=\"noopener noreferrer\" data-extlink=\"\">Operation Warp Speed<\/a>, a multi-agency collaboration led by HHS accelerating the development, manufacturing and distribution of medical countermeasures for COVID-19.<\/p>\n<p>\u201cNIH is committed to supporting several Phase 3 vaccine trials to increase the odds that one or more will be effective in preventing COVID-19 and put us on the road to recovery from this devastating pandemic,\u201d said NIH Director Francis S. Collins, M.D., Ph.D.<\/p>\n<p>The trial will enroll approximately 30,000 adult volunteers at 80 sites in the United States.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Scientists at Rocky Mountain Laboratories in Hamilton, Montana,conducted a preclinical study of the investigational vaccine AZD1222, their findings were recently published in\u00a0Nature.\u00a0 AZD122 uses a viral vector to deliver a SARS-CoV-2 spike protein to induce immune response. See the full news release at Phase 3 Clinical Testing in the US of AstraZeneca COVID-19 Vaccine Candidate&#8230; <a href=\"https:\/\/news.nnlm.gov\/nphco\/covid-19-vaccine-candidate-begins-phase-3-clinical-trial\/\">Read More &raquo;<\/a><\/p>\n","protected":false},"author":1133,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[4],"tags":[],"class_list":["post-928","post","type-post","status-publish","format-standard","hentry","category-blog"],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/news.nnlm.gov\/nphco\/wp-json\/wp\/v2\/posts\/928","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/news.nnlm.gov\/nphco\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/news.nnlm.gov\/nphco\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/news.nnlm.gov\/nphco\/wp-json\/wp\/v2\/users\/1133"}],"replies":[{"embeddable":true,"href":"https:\/\/news.nnlm.gov\/nphco\/wp-json\/wp\/v2\/comments?post=928"}],"version-history":[{"count":2,"href":"https:\/\/news.nnlm.gov\/nphco\/wp-json\/wp\/v2\/posts\/928\/revisions"}],"predecessor-version":[{"id":930,"href":"https:\/\/news.nnlm.gov\/nphco\/wp-json\/wp\/v2\/posts\/928\/revisions\/930"}],"wp:attachment":[{"href":"https:\/\/news.nnlm.gov\/nphco\/wp-json\/wp\/v2\/media?parent=928"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/news.nnlm.gov\/nphco\/wp-json\/wp\/v2\/categories?post=928"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/news.nnlm.gov\/nphco\/wp-json\/wp\/v2\/tags?post=928"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}